General Information of Drug (ID: DMKAIR9)

Drug Name
AZD9574 Drug Info
Synonyms
AZD-9574; AZD9574; 2756333-39-6; 9UG32UQW48; UNII-9UG32UQW48; 2-Pyridinecarboxamide, 6-fluoro-5-(4-((5-fluoro-3,4-dihydro-2-methyl-3-oxo-6-quinoxalinyl)methyl)-1-piperazinyl)-N-methyl-; 6-fluoro-5-[4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl]-N-methylpyridine-2-carboxamide; 6-fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-4H-quinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide; CHEMBL5095223; SCHEMBL24156588; GTPL11946; GLXC-25685; EX-A6177; NSC840950; AKOS040759967; AT34947; NSC-840950; example 20 [WO2021260092A1]; MS-27579; HY-145804; CS-0433406; 6-FLUORO-5-(4-((5-FLUORO-2-METHYL-3-OXO-3,4-DIHYDROQUINOXALIN-6-YL)METHYL)PIPERAZIN-1-YL)-N-METHYLPICOLINAMIDE
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
PubChem CID
162524593
TTD Drug ID
DMKAIR9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Olaparib DM8QB1D Ovarian cancer 2C73 Approved [3]
Rucaparib DM9PVX8 Ovarian cancer 2C73 Approved [4]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [5]
MK-4827 DMLYGH4 Ovarian cancer 2C73 Phase 3 [6]
BSI-201 DMM0VO3 Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Rubraca rucaparib DM25TMP Ovarian cancer 2C73 Phase 3 [8]
ABT-888 DM4HYMS Breast cancer 2C60-2C65 Phase 3 [6]
INO-1001 DM5L8QT Brain cancer 2A00 Phase 3 [9]
BGP-15 DMYDM68 Type-2 diabetes 5A11 Phase 2 [10]
BGB-290 DMRO6XT Ovarian cancer 2C73 Phase 2 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05417594) A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
10 BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.